Sweden Inflammatory Bowel Disease Treatment Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$74.2

Forecast, 2030 (US$M)

$107.5

CAGR, 2024 - 2030

5.4%

Report Coverage

Sweden

Sweden inflammatory bowel disease treatment market, 2018-2030 (US$M)

Related Markets

Global Inflammatory Bowel Disease Treatment Industry Outlook

North America Inflammatory Bowel Disease Treatment Market Outlook

U.S. Inflammatory Bowel Disease Treatment Market Outlook

Canada Inflammatory Bowel Disease Treatment Market Outlook

Europe Inflammatory Bowel Disease Treatment Market Outlook

Germany Inflammatory Bowel Disease Treatment Market Outlook

France Inflammatory Bowel Disease Treatment Market Outlook

Italy Inflammatory Bowel Disease Treatment Market Outlook

Spain Inflammatory Bowel Disease Treatment Market Outlook

Denmark Inflammatory Bowel Disease Treatment Market Outlook

Norway Inflammatory Bowel Disease Treatment Market Outlook

UK Inflammatory Bowel Disease Treatment Market Outlook

Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook

Japan Inflammatory Bowel Disease Treatment Market Outlook

China Inflammatory Bowel Disease Treatment Market Outlook

India Inflammatory Bowel Disease Treatment Market Outlook

Australia Inflammatory Bowel Disease Treatment Market Outlook

South Korea Inflammatory Bowel Disease Treatment Market Outlook

Singapore Inflammatory Bowel Disease Treatment Market Outlook

Thailand Inflammatory Bowel Disease Treatment Market Outlook

Latin America Inflammatory Bowel Disease Treatment Market Outlook

Mexico Inflammatory Bowel Disease Treatment Market Outlook

Argentina Inflammatory Bowel Disease Treatment Market Outlook

Brazil Inflammatory Bowel Disease Treatment Market Outlook

MEA Inflammatory Bowel Disease Treatment Market Outlook

South Africa Inflammatory Bowel Disease Treatment Market Outlook

Saudi Arabia Inflammatory Bowel Disease Treatment Market Outlook

UAE Inflammatory Bowel Disease Treatment Market Outlook

Kuwait Inflammatory Bowel Disease Treatment Market Outlook

Sweden inflammatory bowel disease treatment market highlights

The Sweden inflammatory bowel disease treatment market generated a revenue of USD 74.2 million in 2023 and is expected to reach USD 107.5 million by 2030.
The Sweden market is expected to grow at a CAGR of 5.4% from 2024 to 2030.
In terms of segment, crohn's disease was the largest revenue generating type in 2023.
Ulcerative Colitis is the most lucrative type segment registering the fastest growth during the forecast period.

Inflammatory bowel disease treatment market data book summary

Market revenue in 2023	USD 74.2 million
Market revenue in 2030	USD 107.5 million
Growth rate	5.4% (CAGR from 2023 to 2030)
Largest segment	Crohn's disease
Fastest growing segment	Ulcerative Colitis
Historical data	2018 - 2022
Base year	2023
Forecast period	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Crohn's Disease, Ulcerative Colitis
Key market players worldwide	AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare

Other key industry trends

In terms of revenue, Sweden accounted for 0.4% of the global inflammatory bowel disease treatment market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Europe, Germany inflammatory bowel disease treatment market is projected to lead the regional market in terms of revenue in 2030.
Denmark is the fastest growing regional market in Europe and is projected to reach USD 65.0 million by 2030.

Key Regions: U.S. , UK , Japan , Brazil , UAE

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Inflammatory Bowel Disease Treatment Market Scope

Inflammatory bowel disease treatment market segmentation & scope

Type

Crohn's Disease

Ulcerative Colitis

Drug Class

Aminosalicylates

Corticosteroids

TNF Inhibitors

IL Inhibitors

Anti-integrin

JAK Inhibitors

Other Drug Class

Route of Administration

Oral

Injectable

Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Regions

Europe

Countries

U.S.

Canada

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Japan

China

India

Brazil

Mexico

Argentina

South Africa

Saudi Arabia

UAE

Kuwait

Inflammatory Bowel Disease Treatment Market Companies

Name	Profile	# Employees	HQ	Website

Sweden inflammatory bowel disease treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.

Crohn's disease was the largest segment with a revenue share of 60.38% in 2023. Horizon Databook has segmented the Sweden inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.

Continuous developments by companies operating in the market are contributing to market growth. For instance, in July 2022, AbbVie announced that the European Commission approved RINVOQ for the treatment of severe to moderate ulcerative colitis. The approval is based on phase III study results, and it is RINVOQ’s fifth therapeutic indication in the European Union.

Furthermore, in November 2021, Galapagos NV announced that the European Commission granted marketing authorization to nilotinib 200 mg tablets for the treatment of moderate to severe ulcerative colitis.

In addition, the growing demand for biosimilars in the country is facilitating its market growth. For instance, in October 2018, Amgen announced that AMGEVITA, a biosimilar approved by European Commission, has been authorized for the management of inflammatory diseases, including psoriatic arthritis and moderate-tosevere Crohn's disease & ulcerative colitis.

Reasons to subscribe to Sweden inflammatory bowel disease treatment market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Sweden inflammatory bowel disease treatment market databook

Our clientele includes a mix of inflammatory bowel disease treatment market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Sweden inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Sweden inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.